Senior counsel
Wilson Sonsini Goodrich & Rosati PC
Columns
Title | Category | Published |
---|---|---|
Ruling may diminish ability to avoid induced infringement liability | Intellectual Property | Nov. 16, 2020 |
FDA proposes rule clarifying evidence for determining product’s intended use | Administrative/Regulatory | Nov. 2, 2020 |
EO to ensure drug rebates are passed down to patients | Administrative/Regulatory, Health Care & Hospital Law | Sep. 15, 2020 |
The FDA and qualified health claims: a case study | Administrative/Regulatory | Aug. 12, 2020 |
Bill would bring drugs that treat serious conditions to market faster | Health Care & Hospital Law | Jun. 16, 2020 |
FDA, FTC issue joint statement on efforts to support market for biologics | Administrative/Regulatory, Health Care & Hospital Law | Feb. 24, 2020 |
MCLE
Title | Category | Published |
---|---|---|
The FDA and qualified health claims: a case study | Administrative/Regulatory | Aug. 12, 2020 |
Title | Category | Published |
---|---|---|
Ruling may diminish ability to avoid induced infringement liability | Intellectual Property | Nov. 16, 2020 |
FDA proposes rule clarifying evidence for determining product’s intended use | Administrative/Regulatory | Nov. 2, 2020 |
EO to ensure drug rebates are passed down to patients | Administrative/Regulatory, Health Care & Hospital Law | Sep. 15, 2020 |
The FDA and qualified health claims: a case study | Administrative/Regulatory | Aug. 12, 2020 |
Bill would bring drugs that treat serious conditions to market faster | Health Care & Hospital Law | Jun. 16, 2020 |
FDA, FTC issue joint statement on efforts to support market for biologics | Administrative/Regulatory, Health Care & Hospital Law | Feb. 24, 2020 |
Title | Category | Published |
---|---|---|
The FDA and qualified health claims: a case study | Administrative/Regulatory | Aug. 12, 2020 |